A carregar...
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies
PURPOSE: For immunotherapy, such as checkpoint inhibitors and chimeric antigen receptor T-cell therapy, where the efficacy does not necessarily increase with the dose, the maximum tolerated dose may not be the optimal dose for treating patients. For these novel therapies, the objective of dose-findi...
Na minha lista:
| Publicado no: | JCO Precis Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7713525/ https://ncbi.nlm.nih.gov/pubmed/33283133 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.20.00257 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|